HepB-CpG(HEPLISAV-B)与HepB-Eng(Engerix-B)乙肝疫苗在慢性肾脏病成人中的长期免疫原性与安全性比较
HBV-19为多中心、开放标签、3b期试验,纳入147例既往在HBV-17中完成HepB-CpG或HepB-Eng全程接种的慢性肾脏病成人,评估血清保护持久性。两组血清保护持久性相似,HepB-CpG组抗-HBs几何均值随时间显著高于HepB-Eng组(P ≤ 0.0001),安全性相似。
要点
- 慢性肾脏病成人中HepB-CpG与HepB-Eng的血清保护持久性相似。
- 接种后抗-HBs ≥ 100mIU/mL者中,HepB-CpG组≥ 100mIU/mL持续时间更长。
- HepB-CpG组抗-HBs几何均值随时间显著高于HepB-Eng组(P ≤ 0.0001)。
核心结论
- 因HepB-CpG在慢性肾脏病参与者中诱导更高抗体水平,对HBV的血清保护可能比HepB-Eng持久更久。
研究设计与样本
- HBV-19为多中心、开放标签、3b期试验,纳入147例既往在HBV-17中完成HepB-CpG或HepB-Eng全程接种的慢性肾脏病成人,随访34个月。
- 入组时依据HBV-17中抗-HBs应答将参与者分配至血清保护类别;抗-HBs < 10mIU/mL者接受额外HepB-CpG或HepB-Eng剂量。
主要发现
- 147例参与者中66.7%为男性,中位年龄65.0岁,83.7%为白人。
- 慢性肾脏病参与者中HepB-CpG与HepB-Eng的血清保护持久性相似。
- 接种后抗-HBs ≥ 100mIU/mL者中,HepB-CpG组抗体浓度 ≥ 100mIU/mL持续时间长于HepB-Eng组。
- HepB-CpG组抗-HBs几何均值随时间显著高于HepB-Eng组(P ≤ 0.0001)。
- 两疫苗组安全性特征相似。
关键数值与推荐
- 血清保护定义为抗-HBs浓度 ≥ 10mIU/mL。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis B virus (HBV) infection remains a significant global burden, especially for patients with chronic kidney disease (CKD) receiving hemodialysis. Three doses of HepB-CpG (HEPLISAV-B® vaccine) induced a superior immune response compared with 4 double doses of HepB-Eng (Engerix-B®) in a phase 3 trial (HBV-17) in adults with CKD. Here we report the long-term immunogenicity and safety of HepB-CpG and HepB-Eng in eligible participants of HBV-17 who enrolled in this optional 34-month follow-up trial (HBV-19). METHODS: HBV-19 is a multicenter, open-label, phase 3b trial of adults with CKD who previously received a complete series of HepB-CpG or HepB-Eng in the HBV-17 trial. Participants were assigned to seroprotection categories at enrollment on the basis of their antibody response to hepatitis B surface antigen (anti-HBs) in HBV-17. The objective was to evaluate the durability of seroprotection (defined as an anti-HBs concentration ≥ 10mIU/mL) induced by HepB-CpG and HepB-Eng. Participants whose anti-HBs concentration was below 10mIU/mL received additional HepB-CpG or HepB-Eng doses. RESULTS: 147 participants were enrolled; 66.7 % were men, median age was 65.0 years, and 83.7 % were white. The durability of seroprotection in participants with CKD was similar in those who received HepB-CpG and those who received HepB-Eng. Antibody concentrations ≥ 100mIU/mL persisted for longer in HepB-CpG than HepB-Eng recipients, among those with anti-HBs ≥ 100mIU/mL post vaccination. The geometric mean anti-HBs concentration in the HepB-CpG group was significantly higher than in the HepB-Eng group over time (P ≤ 0.0001). The safety profiles were similar between the vaccine groups. CONCLUSIONS: Due to the higher antibody levels induced by HepB-CpG in participants with CKD, seroprotection against HBV may be expected to persist longer than that induced by HepB-Eng. CLINICALTRIALS: gov: NCT01282762.
引用
- Girndt M, Houser P, Manllo-Karim R, et al. Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease. Vaccine. 2023. PMID: 37085451. doi:10.1016/j.vaccine.2023.04.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。